Market News & Trends
Kynos Therapeutics Announces Positive Top-Line Results From First-in-Human Phase I Study of its KMO Inhibitor
Kynos Therapeutics Ltd recently announced the key findings from the first-in-human Phase 1 trial of its lead drug candidate, KNS366. KMO is an enzyme that…
Salubris Biotherapeutics Announces $35 Million in Financing & Provides Pipeline Progress Update
Salubris Biotherapeutics, Inc. recently announced a new capital infusion of $35 million to fund continued research and development of clinical and preclinical programs. SalubrisBio also…
Nutcracker Therapeutics Demonstrates Positive Data on Anti-Prostate Cancer Therapeutic
Nutcracker Therapeutics, Inc. recently presented two posters at the American Association for Cancer Research (AACR) Annual Meeting in San Diego: one showcasing the latest preclinical data…
Regeneration Biomedical Doses First Patient in a First-in-Human Phase 1 Clinical Trial of Stem Cell Therapy Delivered Directly Into the Brain of Patients With Alzheimer’s Disease
Regeneration Biomedical, Inc. recently announced the first patient has been dosed in an FDA-cleared, first-in-human Phase 1 clinical trial of autologous, Wnt-Activated Adipose-Derived Stem Cells…
Lisata Therapeutics & Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial
Lisata Therapeutics, Inc. and Qilu Pharmaceutical Co., Ltd. recently announced the first patient has been treated in Qilu’s Phase 2 trial in China evaluating LSTA1…
Wave Life Sciences Announces Continued Momentum in GSK Collaboration & Advancements in siRNA & RNA Editing
Wave Life Sciences Ltd. recently provided an update on its best-in-class small interfering RNA (siRNA) and RNA editing platform capabilities. As part of Wave’s ongoing…
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA
Petros Pharmaceuticals, Inc. recently announces it has received positive feedback from the US FDA following the FDA’s informal review of Petros’ technology component for self-selection…
Alvotech & Teva Announce FDA Approval of Biosimilar to Stelara
Alvotech and Teva Pharmaceuticals recently announced the US FDA has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara, for the treatment…
CordenPharma & GENEPEP Celebrate Strong Collaboration Leveraging Peptide Drug Substance Discovery & Clinical Development Expertise
CordenPharma and GENEPEP have recently celebrated 1 year of their fruitful partnership signed in 2023, which supports biotech companies with the development, discovery, and manufacturing…
Atossa Therapeutics & Quantum Leap Healthcare Announce Clinical Trial to Evaluate (Z)-Endoxifen in Combination With Abemaciclib in Women With ER+/HER2- Breast Cancer
Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative recently announced the initiation of a new study to evaluate Atossa’s proprietary (Z)-endoxifen in combination with abemaciclib…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….